Xu Ping, Chen Hui, Xu Junchi, Wu Minjuan, Zhu Xiaoyan, Wang Fengping, Chen Sufang, Xu Junhua
The Affiliated Infectious Hospital of Soochow University, 1 Xier Road, Gusu District, Suzhou City, China; Key Laboratory of Infection and Immunity of Suzhou City, Suzhou City, China.
The Affiliated Infectious Hospital of Soochow University, 1 Xier Road, Gusu District, Suzhou City, China.
Int J Infect Dis. 2017 Jul;60:35-41. doi: 10.1016/j.ijid.2017.05.003. Epub 2017 May 8.
To evaluate the efficacy and safety of the introduction of moxifloxacin into the recommended regimen for tuberculosis (TB) treatment.
A meta-analysis was performed of nine eligible studies regarding the effect of moxifloxacin plus the recommended regimen compared to the recommended regimen alone for the treatment of TB.
In the efficacy analysis, the overall odds ratio (OR) for sputum culture conversion was 1.895 (95% confidence interval (CI) 1.355-2.651, p=0.000), indicating that when moxifloxacin is combined with the recommended regimen, the rate of sputum culture conversion is elevated compared to the recommended regimen alone. The overall OR for recurrence was 0.516 (95% CI 0.342-0.920, p=0.022), suggesting that the introduction of moxifloxacin into the recommended regimen reduces TB relapse after treatment. In the safety analysis, the overall OR was estimated to be 1.001 (95% CI 0.855-1.172, p=0.989), demonstrating that adding moxifloxacin to the recommended regimen does not cause more adverse events during TB treatment.
This meta-analysis suggests that the introduction of moxifloxacin into the recommended regimen for the treatment of non-drug resistant TB improves the clinical outcome by elevating the culture conversion rate and reducing the recurrence rate.
评估将莫西沙星引入推荐的结核病（TB）治疗方案中的疗效和安全性。
对九项符合条件的研究进行荟萃分析，这些研究比较了莫西沙星联合推荐方案与单独使用推荐方案治疗结核病的效果。
在疗效分析中，痰培养转阴的总体比值比（OR）为1.895（95%置信区间（CI）1.355 - 2.651，p = 0.000），表明当莫西沙星与推荐方案联合使用时，痰培养转阴率比单独使用推荐方案时有所提高。复发的总体OR为0.516（95%CI 0.342 - 0.920，p = 0.022），提示将莫西沙星引入推荐方案可降低治疗后结核病的复发率。在安全性分析中，总体OR估计为1.001（95%CI 0.855 - 1.172，p = 0.989），表明在推荐方案中添加莫西沙星在结核病治疗期间不会导致更多不良事件。
这项荟萃分析表明，将莫西沙星引入推荐的非耐药结核病治疗方案中，通过提高培养转阴率和降低复发率改善了临床结局。
